Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson’s disease
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
The innate immune system is implicated in Parkinson's disease (PD), but peripheral in-vivo clinical evidence of the components and driving mechanisms involved and their relationship with clinical heterogeneity and progression to dementia remain poorly explored. We examined changes in peripheral innate immune-related markers in PD cases (n = 41) stratified according to risk of developing early dementia. 'Higher Risk'(HR) (n = 23) and 'Lower Risk' (LR) (n = 18) groups were defined according to neuropsychological predictors and MAPT H1/H2 genotype, and compared to age, gender and genotype-matched controls. Monocyte subsets and expression of key surface markers were measured using flow cytometry. Serum markers including alpha-synuclein, inflammasome-related caspase-1 and bacterial translocation-related endotoxin were measured using quantitative immuno-based assays. Specific markers were further investigated using monocyte assays and validated in plasma samples from a larger incident PD cohort (n = 95). We found that classical monocyte frequency was elevated in PD cases compared to controls, driven predominantly by the HR group, in whom Toll-Like Receptor (TLR)4+ monocytes and monocyte Triggering Receptor Expressed on Myeloid cells-2 (TREM2) expression were also increased. Monocyte Human Leukocyte Antigen (HLA)-DR expression correlated with clinical variables, with lower levels associated with worse cognitive/motor performance. Notably, monocyte changes were accompanied by elevated serum bacterial endotoxin, again predominantly in the HR group. Serum alpha-synuclein and inflammasome-related caspase-1 were decreased in PD cases compared to controls regardless of group, with decreased monocyte alpha-synuclein secretion in HR cases. Further, alpha-synuclein and caspase-1 correlated positively in serum and monocyte lysates, and in plasma from the larger cohort, though no associations were seen with baseline or 36-month longitudinal clinical data. Principal Components Analysis of all monocyte and significant serum markers indicated 3 major components. Component 1 (alpha-synuclein, caspase-1, TLR2+ monocytes) differentiated PD cases and controls in both groups, while Component 2 (endotoxin, monocyte TREM2, alpha-synuclein) did so predominantly in the HR group. Component 3 (classical monocytes, alpha-synuclein) also differentiated cases and controls overall in both groups. These findings demonstrate that systemic innate immune changes are present in PD and are greatest in those at higher risk of rapid progression to dementia. Markers associated with PD per-se (alpha-synuclein, caspase-1), differ from those related to cognitive progression and clinical heterogeneity (endotoxin, TREM2, TLR4, classical monocytes, HLA-DR), with mechanistic and therapeutic implications. Alpha-synuclein and caspase-1 are associated, suggesting inflammasome involvement common to all PD, while bacterial translocation associated changes may contribute towards progression to Parkinson's dementia. Additionally, HLA-DR-associated variations in antigen presentation/clearance may modulate existing clinical disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A guideline of selecting and reporting intraclass correlation coefficients for reliability research
Koo, T. K., & Li, M. Y. (2016) · Journal of Chiropractic Medicine · doi:10.1016/j.jcm.2016.02.012 · Cited by 31,709
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
LPS/TLR4 signal transduction pathway
Lu, Y.-C., Yeh, W.-C., & Ohashi, P. S. (2008) · Cytokine · doi:10.1016/j.cyto.2008.01.006 · Cited by 3,301
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Inflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230 · cited 2×
“Caspase-1, a key component of the inflammasome pathway (Strowig et al., 2012), is produced by many cell types, including monocytes (Shamaa et al.”
BackgroundGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity
Saeed, S., Quintin, J., Kerstens, H. H. D., Rao, N. A., Aghajanirefah, A., Matarese, F., Cheng, S.-C., Ratter, J., Berentsen, K., van der Ent, M. A., et al. (2014) · Science · doi:10.1126/science.1251086 · Cited by 1,761
Intestinal permeability – a new target for disease prevention and therapy
Bischoff, S. C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.-D., Serino, M., Tilg, H., Watson, A., & Wells, J. M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0189-7 · Cited by 1,755 · cited 1×
“intestinal/other mucosal membranes (Bischoff et al., 2014; Kelesidis et al., 2012; Alexopoulou et al., 2017) and thus the findings indicate greater bacterial translocation in PD, particularly in the HR group.”
BackgroundIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974
The fate and lifespan of human monocyte subsets in steady state and systemic inflammation
Patel, A. A., Zhang, Y., Fullerton, J. N., Boelen, L., Rongvaux, A., Maini, A. A., Bigley, V., Flavell, R. A., Gilroy, D. W., Asquith, B., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20170355 · Cited by 946 · cited 1×
“Intermediate and non-classical monocytes may also be more senescent cells, that increase with age (Ziegler-Heitbrock and Hofer, 2013) and derive from further differentiation of classical monocytes in the bone marrow (Ong et al., 2018; Patel et al., 2017).”
BackgroundInflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani, S., Robertson, A. A. B., Butler, M. S., Rowe, D. B., O’Neill, L. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4066 · Cited by 897
T cells from patients with Parkinson’s disease recognize α-synuclein peptides
Sulzer, D., Alcalay, R. N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., McMurtrey, C., Hildebrand, W. H., Mao, X., et al. (2017) · Nature · doi:10.1038/nature22815 · Cited by 866 · cited 1×
“, 2016)(Sulzer et al., 2017), and associations between a more ‘proinflammatory’ cytokine profile at diagnosis and faster motor progression and impaired cognition over 3 years follow-up (Williams-Gray et al.”
BackgroundKim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · cited 2×
“…receptor to DAMPs/PAMPs (e.g. bacterial-derived lipids, amyloids) and endogenous ligands including forms of alpha-synuclein (Bryant et al., 2015; Kim et al., 2013,2016a; Codolo et al., 2013), and can also facilitate activation of the inflammasome pathway (Rapsinski et al., 2015) and caspase-1.”
BackgroundTREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function
Zhao, Y., Wu, X., Li, X., Jiang, L.-L., Gui, X., Liu, Y., Sun, Y., Zhu, B., Piña-Crespo, J. C., Zhang, M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.031 · Cited by 763
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701 · cited 2×
“In the human PD brain, microglial activation has been demonstrated, both at post mortem (McGeer and McGeer, 2008) and in-vivo using Positron Emission Tomography (PET) neuroimaging (Gerhard et al., 2006).”
MethodToll‐like receptor 4 is required for α‐synuclein dependent activation of microglia and astroglia
Fellner, L., Irschick, R., Schanda, K., Reindl, M., Klimaschewski, L., Poewe, W., Wenning, G. K., & Stefanova, N. (2013) · Glia · doi:10.1002/glia.22437 · Cited by 697
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., & LaFerla, F. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2868-05.2005 · Cited by 697 · cited 2×
“Amyloid beta and tau pathology, which are additionally related to cognitive impairment, have also been linked to endotoxin-associated inflammation (Asti and Gioglio, 2014)(Kitazawa et al., 2005), with LPS stimulation leading to increased tau production (Bhaskar et al.”
BackgroundCSF and blood biomarkers for Parkinson's disease
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., & Calabresi, P. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30024-9 · Cited by 673 · cited 1×
“Further, increased aggregated alpha-synuclein species found in PD (Parnetti et al., 2019) may also cause confounding issues with detection by the immunoassays”
BackgroundRegulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639 · cited 1×
“, 2005), with LPS stimulation leading to increased tau production (Bhaskar et al., 2010)(Gardner et al.”
BackgroundTriggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies
Codolo, G., Plotegher, N., Pozzobon, T., Brucale, M., Tessari, I., Bubacco, L., & de Bernard, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055375 · Cited by 585 · cited 3×
“, 2018), have also shown that alpha-synuclein can activate inflammasome pathways causing inflammatory cytokine production (Codolo et al., 2013; Zhou et al., 2016).”
BackgroundMethodCD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570
Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142164 · Cited by 523
Gram-negative bacterial molecules associate with Alzheimer disease pathology
Zhan, X., Stamova, B., Jin, L.-W., DeCarli, C., Phinney, B., & Sharp, F. R. (2016) · Neurology · doi:10.1212/wnl.0000000000003391 · Cited by 521
Role of TLR4 in the gut-brain axis in Parkinson's disease: A translational study from men to mice
Perez-Pardo, P., Dodiya, H. B., Engen, P. A., Forsyth, C. B., Huschens, A. M., Shaikh, M., Voigt, R. M., Naqib, A., Green, S. J., Kordower, J. H., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316844 · Cited by 467 · cited 1×
“intestinal permeability in PD patients, with lower levels of LPS binding protein (LBP) (indicating less LPS neutralisation) and increased gut staining for Escherichia Coli bacteria (Forsyth et al., 2011; Perez-Pardo et al., 2019).”
BackgroundLucas, K., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8425-7 · Cited by 466 · cited 1×
“, 2015), TLR antagonists (Lucas and Maes, 2013)(Peri and Piazza, 2012)(Kouli et al.”
Zhou, Y., Lu, M., Du, R.-H., Qiao, C., Jiang, C.-Y., Zhang, K.-Z., Ding, J.-H., & Hu, G. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0094-3 · Cited by 455
Hamerman, J. A., Jarjoura, J. R., Humphrey, M. B., Nakamura, M. C., Seaman, W. E., & Lanier, L. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2051 · Cited by 440 · cited 2×
“As discussed above, TREM2 is involved in bacterial clearance (Chen et al., 2013) and may be raised in response to elevated endotoxin and TLR signalling in PD (Hamerman et al., 2006; Kober and Brett, 2017).”
BackgroundMacrophages at CNS interfaces: Ontogeny and function in health and disease
Kierdorf, K., Masuda, T., Jordão, M. J. C., & Prinz, M. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0201-x · Cited by 416 · cited 1×
“While monocytes are considered to contribute towards choroid plexus macrophages (Kierdorf et al., 2019), genetic variations in central microglia function have been paralleled in related peripheral monocytes (Bradshaw et al.”
BackgroundHarms, A. S., Cao, S., Rowse, A. L., Thome, A. D., Li, X., Mangieri, L. R., Cron, R. Q., Shacka, J. J., Raman, C., & Standaert, D. G. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5610-12.2013 · Cited by 406
Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., Hatanpaa, K. J., Lomen-Hoerth, C., Kertesz, A., Bigio, E. H., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-19 · Cited by 404
Lee, C. Y. D., Daggett, A., Gu, X., Jiang, L.-L., Langfelder, P., Li, X., Wang, N., Zhao, Y., Park, C. S., Cooper, Y., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.002 · Cited by 396
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET
Sandiego, C. M., Gallezot, J.-D., Pittman, B., Nabulsi, N., Lim, K., Lin, S.-F., Matuskey, D., Lee, J.-Y., O’Connor, K. C., Huang, Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511003112 · Cited by 356
Gao, H.-M., Zhang, F., Zhou, H., Kam, W., Wilson, B., & Hong, J.-S. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1003013 · Cited by 355
Alterations of T-lymphocyte populations in Parkinson disease
Baba, Y., Kuroiwa, A., Uitti, R. J., Wszolek, Z. K., & Yamada, T. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.07.005 · Cited by 336
Dodiya, H. B., Forsyth, C. B., Voigt, R. M., Engen, P. A., Patel, J., Shaikh, M., Green, S. J., Naqib, A., Roy, A., Kordower, J. H., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.12.012 · Cited by 305
Inflammatory dysregulation of blood monocytes in Parkinson’s disease patients
Grozdanov, V., Bliederhaeuser, C., Ruf, W. P., Roth, V., Fundel-Clemens, K., Zondler, L., Brenner, D., Martin-Villalba, A., Hengerer, B., Kassubek, J., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1345-4 · Cited by 295 · cited 3×
“1 Monocyte changes in PD The increase in classical monocytes (with corresponding decrease in non-classical monocytes), and monocyte TLR2+ and TLR4+ monocytes observed in this PD cohort confirms previous findings (Grozdanov et al., 2014)(Drouin-Ouellet et al.”
BackgroundResultInfluentialTREM2-Ligand Interactions in Health and Disease
Kober, D. L., & Brett, T. J. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.004 · Cited by 284
Wang, W., Nguyen, L. T. T., Burlak, C., Chegini, F., Guo, F., Chataway, T., Ju, S., Fisher, O. S., Miller, D. W., Datta, D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610099113 · Cited by 270
Ong, S.-M., Hadadi, E., Dang, T.-M., Yeap, W.-H., Tan, C. T.-Y., Ng, T.-P., Larbi, A., & Wong, S.-C. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0327-1 · Cited by 233
Innate Immune Programing by Endotoxin and Its Pathological Consequences
Morris, M. C., Gilliam, E. A., & Li, L. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00680 · Cited by 224
α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration
Harms, A. S., Delic, V., Thome, A. D., Bryant, N., Liu, Z., Chandra, S., Jurkuvenaite, A., & West, A. B. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0494-9 · Cited by 181
Can a Bacterial Endotoxin be a Key Factor in the Kinetics of Amyloid Fibril Formation?
Asti, A., & Gioglio, L. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131394 · Cited by 180
Increased Immune Activation by Pathologic α‐Synuclein in Parkinson's Disease
Grozdanov, V., Bousset, L., Hoffmeister, M., Bliederhaeuser, C., Meier, C., Madiona, K., Pieri, L., Kiechle, M., McLean, P. J., Kassubek, J., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25557 · Cited by 161
Drouin-Ouellet, J., St-Amour, I., Saint-Pierre, M., Lamontagne-Proulx, J., Kriz, J., Barker, R. A., & Cicchetti, F. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu103 · Cited by 153 · cited 2×
“Studies have specifically found increased numbers of classical monocytes, increased monocyte CCR2, TLR2 and TLR4 expression (Funk et al., 2013; Drouin-Ouellet et al., 2015), enhanced phagocytosis (Grozdanov et al.”
BackgroundResultSelf-citationToll-like receptors and their therapeutic potential in Parkinson’s disease and α-synucleinopathies
Kouli, A., Horne, C. B., & Williams-Gray, C. H. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.042 · Cited by 143 · cited 1×
“, 2015), TLR antagonists (Lucas and Maes, 2013)(Peri and Piazza, 2012)(Kouli et al., 2019), and gut bacterial translocation reduction therapies (Fukui, 2017)(Gangarapu et al.”
BackgroundExposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril
Kim, C., Lv, G., Lee, J. S., Jung, B. C., Masuda-Suzukake, M., Hong, C.-S., Valera, E., Lee, H.-J., Paik, S. R., Hasegawa, M., et al. (2016) · Scientific Reports · doi:10.1038/srep30891 · Cited by 138
Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease
Schröder, J. B., Pawlowski, M., Meyer zu Hörste, G., Gross, C. C., Wiendl, H., Meuth, S. G., Ruck, T., & Warnecke, T. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01081 · Cited by 134
Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2
Kim, C., Lee, H.-J., Masliah, E., & Lee, S.-J. (2016) · Experimental Neurobiology · doi:10.5607/en.2016.25.3.113 · Cited by 92
Pal, G. D., Shaikh, M., Forsyth, C. B., Ouyang, B., Keshavarzian, A., & Shannon, K. M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00306 · Cited by 57
Upregulation of α‐synuclein by lipopolysaccharide and interleukin‐1 in human macrophages
Tanji, K., Mori, F., Imaizumi, T., Yoshida, H., Matsumiya, T., Tamo, W., Yoshimoto, M., Odagiri, H., Sasaki, M., Takahashi, H., et al. (2002) · Pathology International · doi:10.1046/j.1440-1827.2002.01385.x · Cited by 55
Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis
Wijeyekoon, R. S., Kronenberg-Versteeg, D., Scott, K. M., Hayat, S., Jones, J. L., Clatworthy, M. R., Floto, R. A., Barker, R. A., & Williams-Gray, C. H. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00870 · Cited by 50 · cited 4×
“Autologous serum was used to better represent the in-vivo intravascular environment (Wijeyekoon et al., 2018), while the standard medium was used to study the intrinsic uptake ability of the monocytes independent of serum factors.”
BackgroundMethodInfluentialSelf-citationZhang, W., Gao, J.-H., Yan, Z.-F., Huang, X.-Y., Guo, P., Sun, L., Liu, Z., Hu, Y., Zuo, L.-J., Yu, S.-Y., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-016-0308-2 · Cited by 37
Gardner, L. E., White, J. D., Eimerbrink, M. J., Boehm, G. W., & Chumley, M. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.06.007 · Cited by 29
Cited by
Periphery and brain, innate and adaptive immunity in Parkinson’s disease
Harms, A. S., Ferreira, S. A., & Romero-Ramos, M. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02268-5 · Cited by 272
TLR2 and TLR4 in Parkinson’s disease pathogenesis: The environment takes a toll on the gut
Gorecki, A. M., Anyaegbu, C. C., & Anderton, R. S. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00271-0 · Cited by 103
“TLR2 expression is increased in circulating monocytes of people with PD [48, 49].”
BackgroundUpregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease
Kasen, A., Houck, C., Burmeister, A. R., Sha, Q., Brundin, L., & Brundin, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105654 · Cited by 78
Age-Related Adaptive Immune Changes in Parkinson’s Disease
Kouli, A., & Williams-Gray, C. H. (2022) · Journal of Parkinson's Disease · doi:10.3233/jpd-223228 · Cited by 20
Self-citation
Metadata
- Authors
- Wijeyekoon, R. S., Kronenberg-Versteeg, D., Scott, K. M., Hayat, S., Kuan, W.-L., Evans, J. R., Breen, D. P., Cummins, G., Jones, J. L., Clatworthy, M. R., Floto, R. A., Barker, R. A., & Williams-Gray, C. H.
- Venue
- Brain, Behavior, and Immunity
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 87
- Pages
- 473-488
- ISSN
- 0889-1591 (ISSN-L)
- OpenAlex
- W3003257635
- Cited by
- 104
- References
- 56
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.